Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
Presbyopia, the age-related loss of near vision, could soon be treated successfully
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Roche says the move marks a step forward in its digital transformation strategy
Subscribe To Our Newsletter & Stay Updated
